Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Following-up Study

Clinical Trial ID NCT02915354

PubWeight™ 0.00^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02915354

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.	N Engl J Med	2002	6.26
2	Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis.	J Rheumatol	2007	1.63
3	Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab.	Arthritis Res Ther	2005	1.61
4	Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.	Rheumatology (Oxford)	2004	1.37
5	The sacroiliac joint in the spondyloarthropathies.	Curr Opin Rheumatol	1996	1.37
6	Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association.	J Rheumatol	2000	1.37
7	New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy.	Curr Opin Rheumatol	2001	1.09
8	Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population.	Eur J Orthop Surg Traumatol	2012	0.82
9	Abnormal high-expression of CD154 on T lymphocytes of ankylosing spondylitis patients is down-regulated by etanercept treatment.	Rheumatol Int	2009	0.81
10	Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis.	Eur J Health Econ	2014	0.76
11	Withdrawal of medical therapies in axial spondyloarthritis: what would be the optimal trial design?	Clin Exp Rheumatol	2013	0.75